Biogen announced it will showcase new data on its Alzheimer’s disease treatments at the AAIC 2026 conference in London, including Phase 2 results from the CELIA study of diranersen, a tau-targeting antisense oligonucleotide. The data includes clinical, biomarker, and safety findings that support advancing diranersen toward Phase 3 trials. Biogen will also present updates on lecanemab, highlighting subcutaneous administration, real-world use, and three-year outcomes from the LEADER study. These presentations underscore Biogen’s commitment to innovative Alzheimer’s therapies targeting core disease mechanisms like tau and amyloid proteins.
A proposed $18.9 million class action settlement has been approved by a U.S. District Court for investors who purchased Biogen Inc. common stock between June 8 and July 12, 2021. The settlement aims to resolve claims against Biogen and certain execut...
A $18.9 million class action settlement has been approved for investors who bought Biogen Inc. common stock between June 8 and July 12, 2021. The settlement resolves claims against Biogen and certain executives, with a court hearing scheduled for Sep...
Pomerantz LLP is investigating Biogen and some of its executives for potential securities fraud following the company's announcement that its Alzheimer's drug trial failed to meet the primary endpoint. On May 14, 2026, Biogen reported Phase 2 trial r...
